| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CCR.2004.05.015 |
| P8608 | Fatcat ID | release_f62rwzxgerg7fdbx25xgfiyyeu |
| P698 | PubMed publication ID | 15193263 |
| P5875 | ResearchGate publication ID | 8514705 |
| P50 | author | Joan Brugge | Q18631649 |
| Daniel Haber | Q5217393 | ||
| P2093 | author name string | Wei Wang | |
| Anne Barmettler | |||
| Beth Muir | |||
| Dennis C Sgroi | |||
| Gayatry Mohapatra | |||
| Zuncai Wang | |||
| Mark G Erlander | |||
| Wilson Wang | |||
| Xiao-Jun Ma | |||
| Thomas M Baer | |||
| Ulysses Balis | |||
| Ranelle Salunga | |||
| Jerry Younger | |||
| Steven J Isakoff | |||
| Paula D Ryan | |||
| Andrew Fuller | |||
| Barbara Smith | |||
| James Michaelson | |||
| Karleen Habin | |||
| Yen Tran | |||
| Diem Tran | |||
| Edward Enright | |||
| J Todd Tuggle | |||
| Kimberly Stecker | |||
| Ana Tassin | |||
| Atul Bhan | |||
| Eden Estepa-Sabal | |||
| Paul Amon | |||
| P2860 | cites work | Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line | Q29547239 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | tamoxifen | Q412178 |
| P304 | page(s) | 607-616 | |
| P577 | publication date | 2004-06-01 | |
| P1433 | published in | Cancer Cell | Q280018 |
| P1476 | title | A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen | |
| P478 | volume | 5 |
| Q57134612 | Q57134612 |
| Q39124676 | A 16 Yin Yang gene expression ratio signature for ER+/node- breast cancer |
| Q34500627 | A 41-gene signature derived from breast cancer stem cells as a predictor of survival |
| Q33739161 | A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity |
| Q24646455 | A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland |
| Q37038692 | A candidate molecular signature associated with tamoxifen failure in primary breast cancer |
| Q38526448 | A functionally significant cross-talk between androgen receptor and ErbB2 pathways in estrogen receptor negative breast cancer. |
| Q34029272 | A gene expression signature that can predict the recurrence of tamoxifen-treated primary breast cancer |
| Q79529692 | A gene transcription signature of the Akt/mTOR pathway in clinical breast tumors |
| Q40264399 | A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. |
| Q35757194 | A homeobox gene related to Drosophila distal-less promotes ovarian tumorigenicity by inducing expression of vascular endothelial growth factor and fibroblast growth factor-2 |
| Q46799300 | A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer |
| Q34988570 | A novel lung metastasis signature links Wnt signaling with cancer cell self-renewal and epithelial-mesenchymal transition in basal-like breast cancer |
| Q35916012 | A perspective on DNA microarrays in pathology research and practice |
| Q23909226 | A population-based gene signature is predictive of breast cancer survival and chemoresponse |
| Q34658145 | A prognosis classifier for breast cancer based on conserved gene regulation between mammary gland development and tumorigenesis: a multiscale statistical model |
| Q28731800 | A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients |
| Q44615442 | A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation |
| Q38010295 | A roundabout way to cancer |
| Q30443764 | A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery |
| Q30838525 | A stromal gene signature associated with inflammatory breast cancer. |
| Q33407768 | A voting approach to identify a small number of highly predictive genes using multiple classifiers |
| Q28271466 | ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma |
| Q39306235 | ADP ribosylation by PARP-1 suppresses HOXB7 transcriptional activity |
| Q37375359 | Aberrant expression of posterior HOX genes in well differentiated histotypes of thyroid cancers |
| Q85636737 | Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer |
| Q45788484 | Adjuvant treatment: the contribution of expression microarrays |
| Q34132833 | Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastoma |
| Q40068239 | Alpha-6 integrin is necessary for the tumourigenicity of a stem cell-like subpopulation within the MCF7 breast cancer cell line |
| Q35855473 | Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma |
| Q99365608 | An algorithm to quantify intratumor heterogeneity based on alterations of gene expression profiles |
| Q33939753 | An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival |
| Q36742417 | An expression signature of estrogen-regulated genes predicts disease-free survival in tamoxifen-treated patients better than progesterone receptor status. |
| Q33495831 | Analysis of DNA microarray expression data |
| Q34778940 | Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort |
| Q47637451 | Application of a co‑expression network for the analysis of aggressive and non‑aggressive breast cancer cell lines to predict the clinical outcome of patients |
| Q36428743 | Assessment of the prognostic and predictive utility of the Breast Cancer Index (BCI): an NCIC CTG MA.14 study |
| Q46853513 | Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study |
| Q34125826 | Association of HADHA expression with the risk of breast cancer: targeted subset analysis and meta-analysis of microarray data |
| Q30000323 | Association of Protein Translation and Extracellular Matrix Gene Sets with Breast Cancer Metastasis: Findings Uncovered on Analysis of Multiple Publicly Available Datasets Using Individual Patient Data Approach |
| Q37588396 | Association of a HOXB13 variant with breast cancer |
| Q64068561 | Association of white blood cell count with breast cancer burden varies according to menopausal status, body mass index, and hormone receptor status: a case-control study |
| Q39126208 | Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-κB-mediated antiapoptotic pathway |
| Q92309779 | Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet? |
| Q37080948 | BAG-1 predicts patient outcome and tamoxifen responsiveness in ER-positive invasive ductal carcinoma of the breast. |
| Q91713543 | BCL11A Promotes the Progression of Laryngeal Squamous Cell Carcinoma |
| Q35114304 | BCL11A is a triple-negative breast cancer gene with critical functions in stem and progenitor cells |
| Q37585095 | Biological determinants of endocrine resistance in breast cancer |
| Q39667297 | Biological reprogramming in acquired resistance to endocrine therapy of breast cancer. |
| Q33757796 | Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers. |
| Q30408424 | Breast cancer anti-estrogen resistance 3 inhibits transforming growth factor β/Smad signaling and associates with favorable breast cancer disease outcomes |
| Q30245184 | Breast cancer classification and prognostication through diverse systems along with recent emerging findings in this respect; the dawn of new perspectives in the clinical applications |
| Q57112840 | Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis |
| Q36050579 | Breast cancer gene expression profiling: clinical trial and practice implications |
| Q26773761 | Breast cancer intrinsic subtype classification, clinical use and future trends |
| Q29618061 | Breast cancer metastasis: markers and models |
| Q57114951 | Breast cancer vaccination comes to age: impacts of bioinformatics |
| Q83457870 | Breast tumor progression induced by loss of BTG2 expression is inhibited by targeted therapy with the ErbB/HER inhibitor lapatinib |
| Q37689788 | BreastMark: an integrated approach to mining publicly available transcriptomic datasets relating to breast cancer outcome |
| Q47633149 | Building Diversified Multiple Trees for classification in high dimensional noisy biomedical data. |
| Q64118595 | CC chemokines are differentially expressed in Breast Cancer and are associated with disparity in overall survival |
| Q34983912 | CCAAT/enhancer-binding protein beta: its role in breast cancer and associations with receptor tyrosine kinases |
| Q28540790 | CCNA2 is a prognostic biomarker for ER+ breast cancer and tamoxifen resistance |
| Q38028797 | Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? |
| Q28275089 | Cancer genes and the pathways they control |
| Q37150735 | Caveolin-1-/- null mammary stromal fibroblasts share characteristics with human breast cancer-associated fibroblasts |
| Q33331012 | Cell cycle correlated genes dictate the prognostic power of breast cancer gene lists |
| Q34846801 | Ceramide kinase promotes tumor cell survival and mammary tumor recurrence |
| Q31153861 | Challenges of microarray data and the evaluation of gene expression profile signatures |
| Q28383414 | Choline dehydrogenase interacts with SQSTM1/p62 to recruit LC3 and stimulate mitophagy |
| Q47108198 | Clinical applications of urinary cell-free DNA in cancer: current insights and promising future |
| Q37317171 | Clinical impact of high-throughput gene expression studies in lung cancer |
| Q38754717 | Clinical utility of gene-expression signatures in early stage breast cancer |
| Q47094168 | Clinical utility of multigene profiling assays in early-stage breast cancer |
| Q40173723 | Co-amplification of 8p12 and 11q13 in breast cancers is not the result of a single genomic event. |
| Q91722114 | Co-expression of key gene modules and pathways of human breast cancer cell lines |
| Q37131531 | Combining biological gene expression signatures in predicting outcome in breast cancer: An alternative to supervised classification |
| Q33472698 | Comparison of prognostic gene profiles using qRT-PCR in paraffin samples: a retrospective study in patients with early breast cancer |
| Q30434260 | Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy |
| Q33974305 | Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response |
| Q35973348 | Cooperation of the BTB-Zinc finger protein, Abrupt, with cytoskeletal regulators in Drosophila epithelial tumorigenesis |
| Q46031160 | Correction: Somatic mutations in cancer development. |
| Q35949760 | Cross-regulation between FOXA1 and ErbB2 signaling in estrogen receptor-negative breast cancer |
| Q37378012 | Current molecular diagnostics of breast cancer and the potential incorporation of microRNA |
| Q37663610 | Current potential and limitations of molecular diagnostic methods in head and neck cancer |
| Q36477781 | Current trends in molecular classification of adult renal tumors |
| Q37000701 | Cytochrome P450 2D6 and homeobox 13/interleukin-17B receptor: combining inherited and tumor gene markers for prediction of tamoxifen resistance |
| Q36453102 | DNA methylation profiling distinguishes three clusters of breast cancer cell lines |
| Q37401309 | Dapagliflozin: an emerging treatment option in type 2 diabetes |
| Q38859166 | Deacetylation of HSPA5 by HDAC6 leads to GP78-mediated HSPA5 ubiquitination at K447 and suppresses metastasis of breast cancer |
| Q41136265 | Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease |
| Q36309389 | Deregulation of paralogous 13 HOX genes in oral squamous cell carcinoma |
| Q35084044 | Design and multiseries validation of a web-based gene expression assay for predicting breast cancer recurrence and patient survival |
| Q37384844 | Development and validation of gene expression profile signatures in early-stage breast cancer |
| Q64121186 | Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria |
| Q34356351 | Differential gene expression in tamoxifen-resistant breast cancer cells revealed by a new analytical model of RNA-Seq data |
| Q33265960 | Dissection of a metastatic gene expression signature into distinct components |
| Q33244907 | Distinct molecular mechanisms underlying clinically relevant subtypes of breast cancer: gene expression analyses across three different platforms |
| Q33604686 | Does applicability domain exist in microarray-based genomic research? |
| Q31141334 | Double-edged role of G protein-coupled estrogen receptor 1 in breast cancer prognosis: an analysis of 167 breast cancer samples and online data sets |
| Q34147903 | Dysregulation of the homeobox transcription factor gene HOXB13: role in prostate cancer |
| Q33836140 | ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer |
| Q35622059 | Early developments in gene-expression profiling of breast tumors: potential for increasing black-white patient disparities in breast cancer outcomes? |
| Q92889862 | Effects of thrombospondin-4 on pro-inflammatory phenotype differentiation and apoptosis in macrophages |
| Q35795153 | Elevated expression of mitogen-activated protein kinase phosphatase 3 in breast tumors: a mechanism of tamoxifen resistance |
| Q35625533 | Elevation of SIPL1 (SHARPIN) Increases Breast Cancer Risk |
| Q38794088 | Endocrine Therapy in Premenopausal Hormone Receptor-Positive Breast Cancer. |
| Q33974237 | Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer |
| Q37620377 | Epithelial-mesenchymal transition in mouse mammary tumorigenesis |
| Q36215006 | Epsin Family Member 3 and Ribosome-Related Genes Are Associated with Late Metastasis in Estrogen Receptor-Positive Breast Cancer and Long-Term Survival in Non-Small Cell Lung Cancer Using a Genome-Wide Identification and Validation Strategy |
| Q36293853 | Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function |
| Q89480730 | Estrogen-regulated feedback loop limits the efficacy of estrogen receptor-targeted breast cancer therapy |
| Q40108492 | Estrogen-regulated gene expression predicts response to endocrine therapy in patients with ovarian cancer |
| Q36383272 | Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer |
| Q35503492 | Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value |
| Q41135362 | Evaluation of the ability of adjuvant tamoxifen-benefit gene signatures to predict outcome of hormone-naive estrogen receptor-positive breast cancer patients treated with tamoxifen in the advanced setting. |
| Q33761201 | Exploring the link between germline and somatic genetic alterations in breast carcinogenesis |
| Q33377396 | Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue |
| Q31134380 | Expression analysis onto microarrays of randomly selected cDNA clones highlights HOXB13 as a marker of human prostate cancer. |
| Q35794390 | Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine. |
| Q43234010 | Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores. |
| Q33776184 | Expression profiling of formalin-fixed paraffin-embedded primary breast tumors using cancer-specific and whole genome gene panels on the DASL® platform |
| Q34417579 | FLI1 expression is correlated with breast cancer cellular growth, migration, and invasion and altered gene expression. |
| Q39742231 | Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade index (GGI): new tools for ductal carcinoma in situ (DCIS). |
| Q37577925 | Found in transcription: gene expression and other novel blood biomarkers for the early detection of breast cancer |
| Q40030116 | Functional characterization of the HOXB13 promoter region |
| Q33693027 | Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model |
| Q35125752 | Fuzzy logic selection as a new reliable tool to identify molecular grade signatures in breast cancer--the INNODIAG study |
| Q64119667 | GSK3β regulates epithelial-mesenchymal transition and cancer stem cell properties in triple-negative breast cancer |
| Q92281756 | Gene Expression Assays for Early-Stage Hormone Receptor-Positive Breast Cancer: Understanding the Differences |
| Q57139599 | Gene Expression Profiling in Breast Cancer |
| Q36987053 | Gene arrays for diagnosis, prognosis and treatment of breast cancer metastasis |
| Q51905406 | Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. |
| Q54587377 | Gene expression profiling assigns CHEK2 1100delC breast cancers to the luminal intrinsic subtypes. |
| Q24652481 | Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer |
| Q37958156 | Gene expression profiling in breast cancer: classification, prognostication, and prediction |
| Q79709460 | Gene expression profiling of breast cancer |
| Q35989734 | Gene expression profiling of primary breast cancer |
| Q33404889 | Gene expression profiling of the tumor microenvironment during breast cancer progression |
| Q42365301 | Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation |
| Q33261032 | Gene expression signatures of morphologically normal breast tissue identify basal-like tumors |
| Q34559124 | Gene expression signatures that predict outcome of tamoxifen-treated estrogen receptor-positive, high-risk, primary breast cancer patients: a DBCG study |
| Q38555220 | Gene-Expression-Based Predictors for Breast Cancer |
| Q36989824 | Gene-expression microarrays provide new prognostic and predictive tests for breast cancer |
| Q36690245 | Gene-expression signatures in oncology diagnostics |
| Q35832016 | Genetic characterization of breast cancer and implications for clinical management |
| Q36287371 | Genetic polymorphisms and plasma levels of BCL11A contribute to the development of laryngeal squamous cell carcinoma |
| Q30440216 | Genomancy: predicting tumour response to cancer therapy based on the oracle of genetics. |
| Q48674329 | Genome-wide expression profiling as a clinical tool: are we there yet? |
| Q84744697 | Genomic alterations in histopathologically normal breast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficiency |
| Q37523889 | Genomic predictors of outcome and treatment response in breast cancer |
| Q38835169 | Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning |
| Q42259243 | Genomic signatures of breast cancer metastasis |
| Q36303896 | Genomics in breast cancer-therapeutic implications |
| Q33325484 | Genomics of signaling crosstalk of estrogen receptor alpha in breast cancer cells |
| Q96432094 | Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk |
| Q33241218 | Global analysis of the human gastric epithelial transcriptome altered by Helicobacter pylori eradication in vivo |
| Q34857146 | Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. |
| Q80265745 | Global gene expression profiling of formalin-fixed paraffin-embedded tumor samples: a comparison to snap-frozen material using oligonucleotide microarrays |
| Q33227605 | Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia |
| Q60046635 | GradientScanSurv-An exhaustive association test method for gene expression data with censored survival outcome |
| Q34427951 | HOX genes and their role in the development of human cancers. |
| Q36880407 | HOX genes: Major actors in resistance to selective endocrine response modifiers |
| Q81807188 | HOX genes: not just myeloid oncogenes any more |
| Q39085739 | HOXB13 downregulates intracellular zinc and increases NF-κB signaling to promote prostate cancer metastasis |
| Q24650806 | HOXB13 is downregulated in colorectal cancer to confer TCF4-mediated transactivation |
| Q37668201 | HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERα and inducing IL-6 expression |
| Q38629410 | HOXB13 mutations and binding partners in prostate development and cancer: Function, clinical significance, and future directions |
| Q33933887 | HOXB13 promotes androgen independent growth of LNCaP prostate cancer cells by the activation of E2F signaling |
| Q24675458 | HOXB13 promotes ovarian cancer progression |
| Q36903062 | HOXB13:IL17BR and molecular grade index and risk of breast cancer death among patients with lymph node-negative invasive disease. |
| Q41229470 | HOXB9 Expression Correlates with Histological Grade and Prognosis in LSCC. |
| Q33666849 | HOXB9, a gene overexpressed in breast cancer, promotes tumorigenicity and lung metastasis |
| Q36140973 | High-throughput RNAi screening of human kinases identifies predictors of clinical outcome in colorectal cancer patients treated with oxaliplatin |
| Q28077637 | Hormonal Modulation of Breast Cancer Gene Expression: Implications for Intrinsic Subtyping in Premenopausal Women |
| Q37992403 | Hormonal therapy in breast cancer: a model disease for the personalization of cancer care |
| Q36413509 | Host genotype and tumor phenotype of chemokine decoy receptors integrally affect breast cancer relapse |
| Q42220559 | Hoxb13 regulatory elements mediate transgene expression during prostate organogenesis and carcinogenesis |
| Q35698941 | Human CHCHD4 mitochondrial proteins regulate cellular oxygen consumption rate and metabolism and provide a critical role in hypoxia signaling and tumor progression |
| Q81220604 | Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 downregulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy |
| Q92541393 | IL1R2 Blockade Suppresses Breast Tumorigenesis and Progression by Impairing USP15-Dependent BMI1 Stability |
| Q36913636 | Identification and validation of a new set of five genes for prediction of risk in early breast cancer |
| Q36383433 | Identification and validation of gene expression models that predict clinical outcome in patients with early-stage laryngeal cancer |
| Q37661495 | Identification of Marker Genes for Cancer Based on Microarrays Using a Computational Biology Approach. |
| Q33368855 | Identification of a gene signature in cell cycle pathway for breast cancer prognosis using gene expression profiling data |
| Q44654000 | Identification of gene pairs through penalized regression subject to constraints |
| Q34275507 | Identification of high-quality cancer prognostic markers and metastasis network modules |
| Q91329772 | Identification of novel predictive factors for post surgical corneal haze |
| Q37645467 | Identification of phenotype deterministic genes using systemic analysis of transcriptional response |
| Q34091380 | Identification of prognostic genes for recurrent risk prediction in triple negative breast cancer patients in Taiwan. |
| Q33594352 | Identifying tightly regulated and variably expressed networks by Differential Rank Conservation (DIRAC). |
| Q42519161 | Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas). |
| Q47151248 | Impact of the G84E variant on HOXB13 gene and protein expression in formalin-fixed, paraffin-embedded prostate tumours. |
| Q38105253 | Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies |
| Q37214212 | Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis |
| Q33672680 | In situ proteomic analysis of human breast cancer epithelial cells using laser capture microdissection: annotation by protein set enrichment analysis and gene ontology |
| Q36338556 | Increased HOX C13 expression in metastatic melanoma progression |
| Q38451798 | Indications for prognostic gene expression profiling in early breast cancer |
| Q90635071 | Inhibiting PAD2 enhances the anti-tumor effect of docetaxel in tamoxifen-resistant breast cancer cells |
| Q39945691 | Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis |
| Q37968654 | Integrating breast cancer genetics into clinical practice. |
| Q28538685 | Integration of molecular profiling and chemical imaging to elucidate fibroblast-microenvironment impact on cancer cell phenotype and endocrine resistance in breast cancer |
| Q35177024 | Integrative analysis of survival-associated gene sets in breast cancer |
| Q36065268 | Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis |
| Q26771264 | Interleukin-17 Could Promote Breast Cancer Progression at Several Stages of the Disease |
| Q31122465 | Interrogating differences in expression of targeted gene sets to predict breast cancer outcome |
| Q39253863 | Intratumoral estrogen concentration and expression of estrogen-induced genes in male breast carcinoma: comparison with female breast carcinoma |
| Q35576242 | Invasive Breast Cancer: Recognition of Molecular Subtypes |
| Q52653031 | Investigating a multigene prognostic assay based on significant pathways for Luminal A breast cancer through gene expression profile analysis. |
| Q34338152 | Is the 21-gene recurrence score a cost-effective assay in endocrine-sensitive node-negative breast cancer? |
| Q28250373 | Laser capture microdissection technology |
| Q30992101 | Limits of predictive models using microarray data for breast cancer clinical treatment outcome |
| Q55413676 | LncRNA UCA1, Upregulated in CRC Biopsies and Downregulated in Serum Exosomes, Controls mRNA Expression by RNA-RNA Interactions. |
| Q35051765 | Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance |
| Q28308069 | Loss of Rho GDIα and resistance to tamoxifen via effects on estrogen receptor α |
| Q47410836 | MTA1 is a novel regulator of autophagy that induces tamoxifen resistance in breast cancer cells. |
| Q37130478 | MUC1-induced alterations in a lipid metabolic gene network predict response of human breast cancers to tamoxifen treatment |
| Q50420404 | Macrophage-derived lipocalin-2 transports iron in the tumor microenvironment. |
| Q37613240 | Making the case for molecular staging of malignant pleural mesothelioma |
| Q36791451 | Management of breast cancer--Part II. |
| Q35883606 | Med1 plays a critical role in the development of tamoxifen resistance |
| Q38824160 | Melatonergic system-based two-gene index is prognostic in human gliomas |
| Q31147871 | Merging microarray data from separate breast cancer studies provides a robust prognostic test |
| Q36955113 | Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures |
| Q33555064 | Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer |
| Q31158830 | Meta-analytic support vector machine for integrating multiple omics data |
| Q39788006 | MetaKTSP: a meta-analytic top scoring pair method for robust cross-study validation of omics prediction analysis |
| Q37743312 | Metabolomic characterisation of the effects of oncogenic PIK3CA transformation in a breast epithelial cell line |
| Q24646090 | MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype |
| Q42414285 | Microarray data analysis in neoadjuvant biomarker studies in estrogen receptor-positive breast cancer |
| Q23924056 | Microarray profiling in breast cancer patients |
| Q34044075 | Microarray-based cancer prediction using single genes |
| Q37356684 | Microarray-based gene expression profiling as a clinical tool for breast cancer management: are we there yet? |
| Q35558070 | Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction |
| Q37605872 | Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches. |
| Q31151025 | Mistakes in validating the accuracy of a prediction classifier in high-dimensional but small-sample microarray data |
| Q84973866 | Molecular Profiling: Moving Away from Tumor Philately |
| Q37751530 | Molecular basis for therapy resistance |
| Q35383627 | Molecular characterization of the tumor-suppressive function of nischarin in breast cancer |
| Q36642141 | Molecular classification of breast cancer: implications for selection of adjuvant chemotherapy. |
| Q37974614 | Molecular classification of breast carcinomas with particular emphasis on "basal-like" carcinoma: a critical review |
| Q44843862 | Molecular classification of breast phyllodes tumors: validation of the histologic grading scheme and insights into malignant progression |
| Q37722954 | Molecular epidemiology and its current clinical use in cancer management |
| Q33858073 | Molecular genetics complexity impeding research progress in breast and ovarian cancers |
| Q38236904 | Molecular markers for breast cancer diagnosis, prognosis and targeted therapy |
| Q37083949 | Molecular profiles of progesterone receptor loss in human breast tumors |
| Q36803946 | Molecular profiling in breast cancer |
| Q54403385 | Molecular prognostic and predictive markers of breast cancer treatment |
| Q30389146 | Molecular signatures discriminating the male and the female sexual pathways in the pearl oyster Pinctada margaritifera |
| Q37052739 | Molecular subtypes in breast cancer evaluation and management: divide and conquer |
| Q48582963 | Molecular taxonomy of luminal breast cancer in 2015 |
| Q38184381 | Molecular tests as prognostic factors in breast cancer |
| Q55513434 | Multi-Omics Analysis Reveals a HIF Network and Hub Gene EPAS1 Associated with Lung Adenocarcinoma. |
| Q36816034 | Multiple biomarkers in molecular oncology. II. Molecular diagnostics applications in breast cancer management |
| Q34288205 | Mutant p53 drives invasion in breast tumors through up-regulation of miR-155. |
| Q34442193 | Negative regulation of NF-κB by the ING4 tumor suppressor in breast cancer |
| Q36618752 | Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress |
| Q36214336 | Network-based approach to identify prognostic biomarkers for estrogen receptor-positive breast cancer treatment with tamoxifen |
| Q35791695 | Neutropenia Prediction Based on First-Cycle Blood Counts Using a FOS-3NN Classifier |
| Q35836089 | Notch promotes recurrence of dormant tumor cells following HER2/neu-targeted therapy |
| Q24633487 | Novel role for PDEF in epithelial cell migration and invasion |
| Q92541751 | OSbrca: A Web Server for Breast Cancer Prognostic Biomarker Investigation With Massive Data From Tens of Cohorts |
| Q50301832 | Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer. |
| Q36455407 | Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. |
| Q37444430 | Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. |
| Q46768869 | Oxidative stress pathways highlighted in tumor cell immortalization: association with breast cancer outcome |
| Q33883406 | PAM50 gene signatures and breast cancer prognosis with adjuvant anthracycline- and taxane-based chemotherapy: correlative analysis of C9741 (Alliance). |
| Q28708968 | PBOV1 is a human de novo gene with tumor-specific expression that is associated with a positive clinical outcome of cancer |
| Q64940824 | Paralogous HOX13 Genes in Human Cancers. |
| Q36493347 | Pharmacogenetics in the management of breast cancer -- prospects for individualised treatment. |
| Q36338003 | Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma |
| Q43067630 | Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance |
| Q36989546 | Practical implications of gene-expression-based assays for breast oncologists. |
| Q42217265 | Predicting Outcomes of Hormone and Chemotherapy in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) Study by Biochemically-inspired Machine Learning. |
| Q35605850 | Predicting a local recurrence after breast-conserving therapy by gene expression profiling |
| Q33337206 | Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen |
| Q42715876 | Predicting response of bladder cancers to gemcitabine and carboplatin neoadjuvant chemotherapy through genome-wide gene expression profiling |
| Q36691795 | Predicting risk of breast cancer recurrence using gene-expression profiling. |
| Q36117673 | Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients |
| Q37463330 | Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker |
| Q37570901 | Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. |
| Q28743108 | Predictive and prognostic molecular markers for cancer medicine |
| Q34173474 | Predictive relevance of HOXB13 protein expression for tamoxifen benefit in breast cancer |
| Q37569919 | Preinvasive breast cancer |
| Q36238862 | Proangiogenic Properties of Thrombospondin-4. |
| Q33434943 | PrognoScan: a new database for meta-analysis of the prognostic value of genes |
| Q24645449 | Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet |
| Q54495437 | Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer. |
| Q42176304 | Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative |
| Q38464418 | Prognostic influence of BCL2 expression in breast cancer |
| Q35083169 | Prognostic significance of TRIM24/TIF-1α gene expression in breast cancer. |
| Q35034575 | Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial |
| Q21195199 | Prolactin-induced protein mediates cell invasion and regulates integrin signaling in estrogen receptor-negative breast cancer |
| Q36322870 | Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer |
| Q30318419 | Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial (AGO, GBG, EORTC-PBG) comparing 6×FEC versus 3×FEC/3×Docetaxel |
| Q39665946 | Protein interaction network (PIN)-based breast cancer subsystem identification and activation measurement for prognostic modeling |
| Q42677510 | Protein phosphatase 1, regulatory subunit 15B is a survival factor for ERα-positive breast cancer |
| Q34660130 | Protein tyrosine phosphatase 4A2 expression predicts overall and disease-free survival of human breast cancer and is associated with estrogen and progestin receptor status |
| Q33245053 | Proteomics of breast cancer: principles and potential clinical applications |
| Q31138624 | RNA Sequencing of Formalin-Fixed, Paraffin-Embedded Specimens for Gene Expression Quantification and Data Mining |
| Q85241229 | RNA and DNA Microarrays |
| Q36643056 | Re-evaluating early breast neoplasia |
| Q39363790 | Re-expression of microRNA-375 reverses both tamoxifen resistance and accompanying EMT-like properties in breast cancer |
| Q51049666 | Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures. |
| Q34066558 | Relative expression analysis for molecular cancer diagnosis and prognosis |
| Q24289394 | Reliability and reproducibility issues in DNA microarray measurements |
| Q26992299 | Research advances of artemin |
| Q47103384 | Robust method for identification of prognostic gene signatures from gene expression profiles. |
| Q35740262 | Robust two-gene classifiers for cancer prediction |
| Q33404896 | Selecting control genes for RT-QPCR using public microarray data |
| Q33834198 | Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays |
| Q34395225 | Silencing HoxA1 by intraductal injection of siRNA lipidoid nanoparticles prevents mammary tumor progression in mice |
| Q42713219 | Somatic mutations in cancer development |
| Q26786366 | Statistical Methods for Establishing Personalized Treatment Rules in Oncology |
| Q36446875 | Statistical challenges with gene expression studies |
| Q83157193 | Statistical evaluation of quality performance on genomic composite biomarker classifiers |
| Q97686325 | Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies |
| Q33270254 | Successful application of microarray technology to microdissected formalin-fixed, paraffin-embedded tissue |
| Q37010408 | Systems biology and cancer stem cells |
| Q42512337 | TPD52 and NFKB1 gene expression levels correlate with G2 chromosomal radiosensitivity in lymphocytes of women with and at risk of hereditary breast cancer |
| Q24317937 | TSPYL5 suppresses p53 levels and function by physical interaction with USP7 |
| Q38481437 | Tailored chemotherapy based on tumour gene expression analysis: breast cancer patients' misinterpretations and positive attitudes |
| Q51912002 | Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? |
| Q24605762 | Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection |
| Q38859693 | Tamoxifen induces a pluripotency signature in breast cancer cells and human tumors |
| Q36689052 | Tamoxifen therapy benefit predictive signature coupled with prognostic signature of post-operative recurrent risk for early stage ER+ breast cancer |
| Q37172893 | Targeting SphK1 as a new strategy against cancer |
| Q36303996 | Technology insight: Application of molecular techniques to formalin-fixed paraffin-embedded tissues from breast cancer |
| Q35876022 | Technology platforms for pharmacogenomic diagnostic assays |
| Q38741530 | Text Mining of the Electronic Health Record: An Information Extraction Approach for Automated Identification and Subphenotyping of HFpEF Patients for Clinical Trials |
| Q33905783 | The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms |
| Q47137356 | The GDNF Family: A Role in Cancer? |
| Q36029481 | The HOXB13 G84E Mutation Is Associated with an Increased Risk for Prostate Cancer and Other Malignancies |
| Q36438352 | The HOXB13 p.Gly84Glu mutation is not associated with the risk of breast cancer |
| Q30425478 | The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway |
| Q37722452 | The Hox genes and their roles in oncogenesis. |
| Q36437988 | The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. |
| Q37325718 | The Snf1-related kinase, Hunk, is essential for mammary tumor metastasis |
| Q24678045 | The Spemann organizer gene, Goosecoid, promotes tumor metastasis |
| Q37588410 | The dual role of asporin in breast cancer progression |
| Q33372939 | The effects of timing of fine needle aspiration biopsies on gene expression profiles in breast cancers |
| Q39670414 | The endothelin axis stimulates the expression of pro-inflammatory cytokines and pro-migratory molecules in breast cancer. |
| Q46845197 | The evolving role of aromatase inhibitors in the treatment of early-stage breast cancer |
| Q36101379 | The expression ratio of Map7/B2M is prognostic for survival in patients with stage II colon cancer |
| Q36841980 | The fibromatosis signature defines a robust stromal response in breast carcinoma |
| Q35769768 | The impact of expression profiling on prognostic and predictive testing in breast cancer |
| Q38587521 | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer |
| Q34330564 | The macrophage colony-stimulating factor 1 response signature in breast carcinoma |
| Q34311300 | The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer |
| Q34752938 | The molecular pathology of breast cancer progression |
| Q33241398 | The molecular portraits of breast tumors are conserved across microarray platforms |
| Q33401257 | The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression |
| Q33915129 | The pathology of EMT in mouse mammary tumorigenesis |
| Q34348172 | The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients |
| Q24310299 | The prolyl 3-hydroxylases P3H2 and P3H3 are novel targets for epigenetic silencing in breast cancer |
| Q37386133 | The rapamycin-regulated gene expression signature determines prognosis for breast cancer |
| Q33745034 | The regulation of miRNA-211 expression and its role in melanoma cell invasiveness |
| Q35191588 | The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer |
| Q37705845 | The small heat shock protein B8 (HSPB8) modulates proliferation and migration of breast cancer cells |
| Q37168029 | The tspair package for finding top scoring pair classifiers in R. |
| Q35191593 | The type III TGF-beta receptor suppresses breast cancer progression |
| Q64262974 | Three inflammation-related genes could predict risk in prognosis and metastasis of patients with breast cancer |
| Q47402505 | Thrombospondin-4 in tissue remodeling |
| Q43400597 | Thrombospondin-4 mediates TGF-β-induced angiogenesis |
| Q34637308 | Thymosin beta-NB is the human isoform of rat thymosin beta15. |
| Q37333606 | Transcriptional regulation of cell polarity in EMT and cancer |
| Q34552025 | Transcriptional shift identifies a set of genes driving breast cancer chemoresistance |
| Q38165072 | Two-gene expression ratio as predictor for breast cancer treated with tamoxifen: evidence from meta-analysis |
| Q52680490 | UBASH3B promotes tamoxifen resistance and could be negatively regulated by ESR1. |
| Q53980821 | Understanding Biomarkers in Early-Stage Invasive Breast Cancer: Tools From the ASCO Clinical Guideline. |
| Q36400527 | Urinary Nucleic Acid TSPAN13-to-S100A9 Ratio as a Diagnostic Marker in Prostate Cancer |
| Q30371443 | Utilizing the molecular gateway: the path to personalized cancer management. |
| Q39501060 | Weighted K-means support vector machine for cancer prediction |
| Q28385778 | Yin Yang gene expression ratio signature for lung cancer prognosis |
| Q38750948 | ZNF503/Zpo2 drives aggressive breast cancer progression by down-regulation of GATA3 expression |
| Q35218681 | c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1 |
| Q35633721 | p66 Shc and tyrosine-phosphorylated Shc in primary breast tumors identify patients likely to relapse despite tamoxifen therapy |
| Q39510266 | shinyGEO: a web-based application for analyzing gene expression omnibus datasets |
Search more.